
Journal of Diagnostics Concepts & Practice››2024,Vol. 23››Issue (06): 587-593.doi:10.16150/j.1671-2870.2024.06.005
Previous ArticlesNext Articles
ZHANG Junhua1,2, LI Yilin3, XIE Jingyuan2, ZHANG Chunli2, XU Jing2(
)
Received:2024-06-27Online:2024-12-25Published:2024-12-25Table 1
Clinical data of the patients
| Index | case1 | case2 | case3 | case4 | case5 | case6 | case7 |
|---|---|---|---|---|---|---|---|
| Baseline data | |||||||
| Gender | Female | Female | Female | Female | Male | Male | Male |
| Age of onset(years) | 51 | 42 | 58 | 18 | 54 | 58 | 26 |
| Age at diagnosis(years) | 51 | 54 | 64 | 23 | 57 | 58 | 29 |
| Follow up(months) | 3 | 108 | 48 | 72 | 144 | 84 | 0 |
| Family history | No | No | No | No | No | No | No |
| SP(mmHg) | 137 | 118 | 128 | 120 | 124 | 180 | 138 |
| DP(mmHg) | 81 | 90 | 89 | 74 | 86 | 96 | 85 |
| NS | No | No | Yes | No | No | No | Yes |
| 24 h TUP(mg) | 2274 | 1632 | 4092 | 1508 | 877 | 1538 | 6301 |
| Microscopic hematuria(/HP) | 11-15 | 6-11 | 4-5 | Full field | 6-10 | 4-5 | 0 |
| Scr(μmol/L) | 175 | 55 | 102 | 47 | 94 | 113 | 78 |
| eGFR(mL/min) | 28.6 | 114.5 | 49.2 | 134.1 | 79.8 | 61.4 | 116 |
| sAlb(g/L) | 25 | 26 | 26 | 30 | 30 | 33 | 29 |
| C3(g/L) | 0.28 | 0.06 | 0.6 | 0.6 | 0.56 | 0.62 | 0.43 |
| C4(g/L) | 0.1 | 0.1 | 0.18 | 0.12 | 0.12 | 0.2 | 0.18 |
| Hb(g/L) | 119 | 113 | 92 | 108 | 115 | 122 | 150 |
| Therapy | MMF+P | ARB+P | ARB+P+CYC | ARB | ARB+P+MMF | ARB | ARB+P+CYC |
| Remission time(months) | 3 | 3 | 2 | 3 | 32 | No | NA |
| Relapse(months) | NA | 18 | No | 46 | 67 | No | NA |
| Follow up for 2 years data | |||||||
| Therapy | NA | ARB+P+CNI | ARB | ARB | ARB+P+MMF | ARB+P+MMF | NA |
| 24 h TUP(mg) | NA | 1542 | 155 | 954 | 352 | 2273 | NA |
| Scr(μmol/L) | NA | 62 | 78 | 54 | 100 | 157 | NA |
| eGFR(ml/min) | NA | 991 | 68.1 | 142.1 | 72.6 | 43.25 | NA |
| sAlb(g/L) | NA | 29 | 42 | 33 | 35 | 27 | NA |
| C3(g/L) | NA | 0.06 | NA | 0.08 | 0.64 | NA | NA |
| C4(g/L) | NA | 0.1 | NA | 0.1 | 0.1 | NA | NA |
| Follow up for 6 years data | |||||||
| Therapy | NA | ARB+P+CNI | NA | ARB | ARB+P+RTX | ARB+P+MMF | NA |
| 24 h TUP(mg) | NA | 1236 | NA | 354 | 6013 | 3627 | NA |
| Scr(μmol/L) | NA | 69 | NA | 51 | 131 | 202 | NA |
| eGFR(mL/min) | NA | 96 | NA | 126.9 | 53.5 | 29.2 | NA |
| sAlb(g/L) | NA | 29 | NA | 39 | 17 | 26 | NA |
| C3(g/L) | NA | 0.07 | NA | 0.46 | 0.59 | NA | NA |
| C4(g/L) | NA | 0.1 | NA | 0.2 | 0.2 | NA | NA |
Table 2
Histological characteristics of the patients
| Index | case1 | case2* | case3* | case4* | case5 | case6 | case7 |
|---|---|---|---|---|---|---|---|
| Light microscope(LM) | |||||||
| Glomerulus(n) | 36 | 6 | 33 | 29 | 19 | 22 | 39 |
| Glomerulosclerosis(n,%) | 2(5.6) | 0(0) | 3(9) | 0(0) | 3(15.8) | 5(26.3)↑ | 12(30.8)↑ |
| Segmental sclerosis(n) | 2 | 0 | 0 | 2 | 0 | 0 | 5 |
| Endocapillary proliferation | ↑ | ↑ | ↑ | ↑ | no | no | no |
| Neutrophils in capillaries | ↑ | ↑ | ↑ | ↑ | no | no | no |
| GBM pseudo double track | non-Dif | non-Dif | non-Dif | non-Dif | Dif | Dif | Dif |
| Mesangial matrix increased | sev | sev | sev | sev | mod | sev | sev |
| Mesangial cells increased | mild | sev | sev | sev | mod | sev | mod |
| Interstitial fibrosis | mild | mild | mild | mild | mild | mod | mod |
| Tubules atrophic | mild | mild | mild | mild | mild | mod | mod |
| Interstitial inflammatory cell | mild | mild | sev | mild | mild | mod | mod |
| Immunofluorescence(IF) | |||||||
| Deposition of C3 | mod | sev | sev | sev | mod | mod | mod |
| Other immune complexes | no | ↑ | no | ↑ | no | ↑ | no |
| Electron microscope(EM) | |||||||
| Electron dense deposits | |||||||
| Mesangial zone | mild | mild | mild | no | sev | mod | mod |
| Epithelial side | no | mild | mild | no | no | no | mod |
| Subepithelial | no | no | mild | mild | mild | mod | mod |
| GBM | no | no | mild | no | no | no | mod |
| Foot process fusion | Dif | Dif | Dif | no | Dif | no | Dif |
Figure 1
Renal pathological findings in C3G Note: A: Jones staining showed diffuse double tracks (×400) in the glomerular basement membrane;B: Periodic Acid-Schiff staining showed diffuse capillary increased cells (×400);C: Jones staining showed segmental double tracks in the glomerular basement membranestaining ;D: Hematoxylin-eosin staining showed neutrophil infiltration in the glomerular capillary lumen (×400);E: Frozen immunofluorescence C3 (+++), capillary loop, mesangial area, diffuse (×400);F: Frozen immunofluorescence C3 (+~++), capillary loop, mesangial area, diffuse (×400);G: Diffuse mesangial cell proliferation and electron dense deposition in the diffuse mesangial area under electron microscope (×2 000); H: Infiltration of inflammatory cells in the capillary lumen under electron microscope (×4 000)
| [1] | MEHDI A, TALIERCIO J J. C3glomerulopathy[J].Cleve Clin J Med,2023,90(6 suppl 1):e1-e4. |
| [2] | SETHI S, DE VRIESE A S, FERVENZA F C. Acute glomerulonephritis[J].Lancet,2022,399(10335):1646-1663. doi:10.1016/S0140-6736(22)00461-5pmid:35461559 |
| [3] | DE VRIESE A S, SETHI S, VAN PRAET J, et al. Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach[J].J Am Soc Nephrol,2015,26(12):2917-2929. |
| [4] | ZIPFEL P F, WIECH T, STEA E D, et al.CFHRgene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy[J].J Am Soc Nephrol,2020,31(2):241-256. |
| [5] | LEMAIRE M, NOONE D, LAPEYRAQUE A L, et al. Inherited kidney complement diseases[J].Clin J Am Soc Nephrol,2021,16(6):942-956. |
| [6] | BARBOUR T D, PICKERING M C, TERENCE COOK H. Dense deposit disease and C3glomerulopathy[J].Semin Nephrol,2013,33(6):493-507. |
| [7] | 车丽双, 林威远. C3肾小球病的诊治进展[J].慢性病学杂志,2022,23(07):1040-1042. |
| CHE L S, LIN W Y. Progress in the diagnosis and treatment of C3 glomerulopathy[J].Chronic Pathematology J,2022,23(07):1040-1042. | |
| [8] | BOMBACK A S, SANTORIELLO D, AVASARE R S, et al. C3glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3glomerulopathy[J].Kidney Int,2018,93(4):977-985. |
| [9] | MEDJERAL-THOMAS N R, O'SHAUGHNESSY M M, O'REGAN J A, et al. C3glomerulopathy: clinicopathologic features and predictors of outcome[J].Clin J Am Soc Nephrol,2014,9(1):46-53. |
| [10] | SERVAIS A, NOËL L H, ROUMENINA L T, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3glomerulopathies[J].Kidney Int,2012,82(4):454-464. |
| [11] | HOU J, REN K Y M, HAAS M. C3 glomerulopathy: a review with emphasis on ultrastructural features[J].Glomerular Dis,2022,2(3):107-120. |
| [12] | NIEPOLSKI L, CZEKAŁA A, SEGET-DUBANIEWICZ M, et al. Diagnostic problems in C3glomerulopathy[J].Biomedicines,2023,11(4):1101. |
| [13] | 魏瑾莹, 黄瑶, 袁曙光, 等. C3沉积为主的肾小球肾炎52例临床与病理特征[J].中南大学学报(医学版),2024,49(1):75-83. |
| WEI J Y, HUANG Y, YUAN S G, et al. Clinical and pathological characteristics of 52 cases of glomerulonephritis with C3deposition as the main component[J].J Cent South Univ (Med Sci),2024,49(1):75-83. | |
| [14] | PICKERING M C, D'AGATI V D, NESTER C M, et al. C3glomerulopathy: consensus report[J].Kidney Int,2013,84(6):1079-1089. |
| [15] | PıNARBAŞı A S, DURSUN I, GOKCE I, et al. Predictors of poor kidney outcome in children with C3glomerulopathy[J].Pediatr Nephrol,2021,36(5):1195-1205. |
| [16] | SMITH R J H, APPEL G B, BLOM A M, et al. C3glomerulopathy - understanding a rare complement-driven renal disease[J].Nat Rev Nephrol,2019,15(3):129-143. |
| [17] | ANDERS H J, KITCHING A R, LEUNG N, et al. Glomerulonephritis: immunopathogenesis and immunotherapy[J].Nat Rev Immunol,2023,23(7):453-471. |
| [18] | LAFAYETTE R A, CHARU V. Expert discussion on challenges in C3G diagnosis: a podcast article on best practices in kidney biopsies[J].Adv Ther,2023,40(12):5557-5566. doi:10.1007/s12325-023-02654-3pmid:37751024 |
| [19] | VISWANATHAN G K, NADA R, KUMAR A, et al. Clinico-pathologic spectrum of C3glomerulopathy-an Indian experience[J].Diagn Pathol,2015,10:6. |
| [20] | HOU J, MARKOWITZ G S, BOMBACK A S, et al. Toward a working definition of C3glomerulopathy by immunofluorescence[J].Kidney Int,2014,85(2):450-456. |
| [1] | XU Tu, SHI Chuntao, HAN Wei, YAO Liqian, CHEN Chaobo, FANG Ling, GU Tingting.Synergistic expression of survivin and TK1 in breast cancer tissues and its clinical significance[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(05): 518-528. |
| [2] | ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei.Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(03): 286-292. |
| [3] | LI Zhuohan, HUANG Xinyun, GUO Rui, YI Hongmei, XU Pengpeng, WU Zhifang, LI Biao.Prognostic value of PET/CT characteristics and combined IPI in follicular lymphoma and diffuse large B-cell lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2025, 24(02): 178-186. |
| [4] | RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun.Study on clinicopathological features and prognosis of HER2 low expression breast cancer[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(05): 500-508. |
| [5] | WANG Yurong, WANG Yuanyuan, WENG Haiyan.Clinical and pathological analysis of gastrointestinal leiomyosarcoma:Report of three cases[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(05): 537-541. |
| [6] | LI Zhuohan, HUANG Xinyun, GUO Rui, LI Biao.18F-FDG PET/CT in the diagnosis and prognosis evaluation of follicular lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(04): 439-444. |
| [7] | ZHU Weiwei, LI Qian, WU Fan, ZHAI Zhimin.Gene mutations and their relationship with clinical features in 100 patients with myelodysplastic syndrome[J]. Journal of Diagnostics Concepts & Practice, 2024, 23(03): 305-312. |
| [8] | WANG Shukui, GU Xinliang.Advances in the study of tsRNA as diagnostic and prognostic biomarkers in cancer[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 413-420. |
| [9] | LIU Yingting, YI Hongmei, WANG Xue, YANG Chunxue, OUYANG Binshen XU Haimin, WANG Chaofu.Clinicopathological features and prognosis of 17 cases of duodenal-type follicular lymphoma[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 362-368. |
| [10] | ZHANG Lanlan, YANG Qiao, NIE Zunzhen, GUO Ying.Thoracic SMARCA4-deficient undifferentiated tumour: a case report[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 389-392. |
| [11] | HU Jingjing, SHEN Yinzhong, LIU Li, LU Hongzhou.Current status and research progress of diagnosis and treatment of AIDS with disseminated non-tuberculous mycobacterial disease[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(04): 402-406. |
| [12] | XU Li, GAO Huajie, YANG Mengge, LI Yue, JI Suqiong.Clinical characteristics of anti-SRP antibody positive immune-mediated necrotizing myopathy with anti-TRIM21/Ro52 antibody positive[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 247-254. |
| [13] | ZHOU Xiaodie, CHEN Weiwei, YU Bo, WANG Xuan, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei.Clinicopathological features of urothelial carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(03): 292-299. |
| [14] | SONG Luqian, CHANG Chunkang.Interpretation of clinical practice guidelines for myelodysplastic syndrome (version 1, 2023) of National Comprehensive Cancer Nerwork(NCCN)[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(02): 116-120. |
| [15] | XU Jiankun, ZHOU Luting, ZHANG Wenjing, XU Haimin, WANG Chaofu.The prognostic value of CA9 expression in clear cell renal cell carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 37-43. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||